See more : The Fahey Banking Company (FAHE) Income Statement Analysis – Financial Results
Complete financial analysis of ORIC Pharmaceuticals, Inc. (ORIC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of ORIC Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Tanaka Co.,Ltd. (7619.T) Income Statement Analysis – Financial Results
- Delivery Consulting Inc. (9240.T) Income Statement Analysis – Financial Results
- Wanma Technology Co., Ltd. (300698.SZ) Income Statement Analysis – Financial Results
- Black Diamond Therapeutics, Inc. (BDTX) Income Statement Analysis – Financial Results
- Delaware Investments Dividend and Income Fund, Inc. (DDF) Income Statement Analysis – Financial Results
ORIC Pharmaceuticals, Inc. (ORIC)
About ORIC Pharmaceuticals, Inc.
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms. It has a license and collaboration agreement with Voronoi Inc.; and a license agreement with Mirati Therapeutics, Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 1.03M | 966.00K | 897.00K | 970.00K | 1.00M | 900.00K | 900.00K |
| Gross Profit | -1.03M | -966.00K | -897.00K | -970.00K | -1.00M | -900.00K | -900.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 85.17M | 61.68M | 56.86M | 35.92M | 22.84M | 19.03M | 19.13M |
| General & Administrative | 25.61M | 25.09M | 22.01M | 13.42M | 5.73M | 3.35M | 3.42M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -900.00K |
| SG&A | 25.61M | 25.09M | 22.01M | 13.42M | 5.73M | 3.35M | 2.52M |
| Other Expenses | 0.00 | 5.00M | 15.00K | 177.00K | 289.00K | 233.00K | 0.00 |
| Operating Expenses | 110.78M | 86.77M | 78.87M | 49.34M | 28.57M | 22.37M | 21.64M |
| Cost & Expenses | 110.78M | 86.77M | 78.87M | 49.34M | 28.57M | 22.37M | 22.54M |
| Interest Income | 10.08M | 2.65M | 141.00K | 306.00K | 1.40M | 775.00K | 251.00K |
| Interest Expense | 0.00 | 2.65M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.03M | 966.00K | 897.00K | 970.00K | 1.00M | 900.00K | 900.00K |
| EBITDA | -109.75M | -91.77M | -77.97M | -74.19M | -27.54M | -20.46M | -21.13M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -110.78M | -91.77M | -78.87M | -74.19M | -28.57M | -22.37M | -22.54M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 10.08M | 2.65M | 156.00K | 483.00K | 1.69M | 1.01M | 512.00K |
| Income Before Tax | -100.70M | -89.12M | -78.72M | -73.70M | -26.88M | -21.36M | -22.03M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 2.36M | -1.04M | 23.57M | -1.40M | -1.01M | 0.00 |
| Net Income | -100.70M | -91.48M | -77.68M | -97.27M | -25.49M | -21.36M | -22.03M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.96 | -2.31 | -2.05 | -4.43 | -0.85 | -1.12 | -0.74 |
| EPS Diluted | -1.96 | -2.31 | -2.05 | -4.43 | -0.85 | -1.12 | -0.74 |
| Weighted Avg Shares Out | 51.45M | 39.66M | 37.95M | 21.94M | 29.90M | 19.14M | 29.90M |
| Weighted Avg Shares Out (Dil) | 51.45M | 39.66M | 37.95M | 21.94M | 29.90M | 19.14M | 29.90M |
3 Stocks at the Forefront of Personalized Medicine Trend
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
ORIC Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operational Updates
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
ORIC Pharmaceuticals to Present Initial Phase 1b Clinical Data for ORIC-533 in Multiple Myeloma at the 65th American Society of Hematology (ASH) Annual Meeting
Initial Phase 1 Dose Escalation Data of ORIC-114 in Patients with EGFR and HER2 Exon 20 Mutations Demonstrates Potential Best-In-Class Profile
ORIC Pharmaceuticals to Present Initial Phase 1b Clinical Data for ORIC 114 in EGFR/HER2 Exon 20 Mutated NSCLC at the European Society of Medical Oncology (ESMO) Congress 2023
Oric Pharmaceuticals, Inc. (ORIC) Upgraded to Buy: What Does It Mean for the Stock?
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Source: https://incomestatements.info
Category: Stock Reports